-

05:43:09 PM

TERN Stock News

TERN - Terns Pharmaceuticals Inc

06/22/22 4:05 PM

Nasdaq : TERN

clinical triallow float

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers -Additional presentations to detail clinical data from Tern’s extensive pipeline, including

RHEA-AI

neutral

06/08/22 4:05 PM

Nasdaq : TERN

conferencesclinical triallow float

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as

RHEA-AI

neutral

06/01/22 4:05 PM

Nasdaq : TERN

managementlow float

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule

RHEA-AI

neutral

05/16/22 4:05 PM

Nasdaq : TERN

earningslow float

Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023 -TERN-601 (GLP-1R agonist) IND-enabling studies underway; Phase 1 clinical trial initiation for obesity expected

RHEA-AI

neutral

04/04/22 4:05 PM

Nasdaq : TERN

conferenceslow float

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as

RHEA-AI

neutral

03/21/22 4:05 PM

Nasdaq : TERN

clinical triallow float

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as

RHEA-AI

very negative

03/03/22 4:05 PM

Nasdaq : TERN

earningslow float

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist) planned for first half of 2022 with top-line data expected in second half of

RHEA-AI

negative

02/28/22 4:05 PM

Nasdaq : TERN

conferenceslow float

Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as

RHEA-AI

neutral

01/06/22 7:05 AM

Nasdaq : TERN

managementlow float

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as

RHEA-AI

positive

01/03/22 4:05 PM

Nasdaq : TERN

conferenceslow float

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as

RHEA-AI

neutral